Related Experiment Video
Updated: Jul 29, 2025
04:49
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
Published on: December 12, 2019
9.3K
Manufacturing innovation to drive down cell therapy costs.
Minsoo Khang1, Smruthi Suryaprakash1, Megan Kotrappa2
1Boston Consulting Group, Boston, MA, USA.
Trends in Biotechnology
|May 26, 2023
Summary
Chimeric antigen receptor T-cell (CAR-T) therapies show promise for cancer treatment, but manufacturing hurdles persist. Innovations in areas like gene engineering and point-of-care production aim to overcome these challenges and unlock CAR-T
Area of Science:
- Immunotherapy
- Biotechnology
- Cancer Treatment
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy is a promising approach for cancer treatment.
- Significant challenges exist in the manufacturing of CAR-T therapies, hindering widespread clinical application.
Purpose of the Study:
- To explore various manufacturing innovations that could enhance CAR-T therapy production.
- To identify key areas of innovation that may enable the full potential of CAR-T therapies.
Main Methods:
- Review of current manufacturing innovations in CAR-T therapy.
- Categorization of innovations into vector and gene engineering, process improvements, hardware, digital technology, and point-of-care manufacturing.
Main Results:
- Multiple innovations across different domains show potential to improve CAR-T manufacturing.
- Specific examples include advancements in vector design, process optimization, novel hardware, digital tools, and decentralized point-of-care models.
Conclusions:
- Manufacturing innovations are crucial for realizing the full therapeutic potential of CAR-T cells.
- Addressing manufacturing challenges through diverse innovations can accelerate the clinical translation and accessibility of CAR-T therapies.
